A detailed history of Los Angeles Capital Management LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 20,033 shares of SUPN stock, worth $723,992. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,033
Holding current value
$723,992
% of portfolio
0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$25.77 - $35.16 $516,250 - $704,360
20,033 New
20,033 $624,000
Q2 2023

Aug 03, 2023

BUY
$29.91 - $38.73 $720,980 - $933,586
24,105 New
24,105 $724,000
Q2 2021

Aug 05, 2021

SELL
$26.72 - $33.19 $395,990 - $491,875
-14,820 Reduced 39.51%
22,690 $699,000
Q1 2021

May 05, 2021

BUY
$24.15 - $31.45 $401,614 - $523,013
16,630 Added 79.65%
37,510 $982,000
Q4 2020

Feb 04, 2021

BUY
$17.7 - $25.81 $369,576 - $538,912
20,880 New
20,880 $525,000
Q3 2020

Nov 02, 2020

SELL
$20.2 - $25.05 $221,311 - $274,447
-10,956 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$17.09 - $24.89 $10,852 - $15,805
635 Added 6.15%
10,956 $260,000
Q1 2020

May 04, 2020

SELL
$14.45 - $24.69 $90,384 - $154,435
-6,255 Reduced 37.74%
10,321 $186,000
Q2 2019

Jul 29, 2019

BUY
$29.96 - $38.87 $496,616 - $644,309
16,576 New
16,576 $548,000
Q4 2018

Feb 11, 2019

SELL
$30.84 - $49.51 $650,446 - $1.04 Million
-21,091 Closed
0 $0
Q3 2018

Nov 05, 2018

BUY
$42.7 - $56.55 $16,226 - $21,489
380 Added 1.83%
21,091 $1.06 Million
Q2 2018

Jul 31, 2018

SELL
$44.1 - $59.85 $276,948 - $375,858
-6,280 Reduced 23.27%
20,711 $1.24 Million
Q1 2018

Apr 27, 2018

BUY
$37.15 - $46.9 $4,643 - $5,862
125 Added 0.47%
26,991 $1.24 Million
Q4 2017

Feb 05, 2018

BUY
$36.4 - $42.6 $502,502 - $588,093
13,805 Added 105.7%
26,866 $1.07 Million
Q3 2017

Nov 06, 2017

BUY
$36.75 - $49.65 $479,991 - $648,478
13,061
13,061 $522,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.